Monotherapy with carbon ion radiation for localized prostate cancer

被引:9
作者
Shimazaki, Jun [1 ]
Akakura, Koichiro
Suzuki, Hiroyoshi
Ichikawa, Tomohiko
Tsuji, Hiroshi
Ishikawa, Hitoshi
Harada, Masaoki
Tsujii, Hirohiko
机构
[1] Chiba Univ, Grad Sch Med, Dept Urol, Chuo Ku, Chiba 2608670, Japan
[2] Natl Inst Radiol Sci, Res Ctr Charged Part Therapy, Chiba, Japan
[3] Kanagawa Canc Ctr, Dept Surg Pathol, Yokohama, Kanagawa, Japan
关键词
prostate cancer; localized stage; radiotherapy; carbon ion radiation;
D O I
10.1093/jjco/hyl030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Radiation treatment for localized prostate cancer has become a prominent choice of monotherapy, and carbon ion beam is a powerful means for this purpose. Methods: In total, 37 patients with localized prostate cancer were treated by monotherapy with carbon ion radiation and the outcome, more than 4 years later, was followed. Results: PSA relapse-free survival was overall 85%, 5 years after radiation, and 96% in low-risk patients. Local control was mostly achieved, and no cancer-specific death was obtained. Except in cases of relapse, 1.0 ng/ml or less of PSA was shown in 78%, 3 years after radiation. Half of biopsy specimens out of 12 cases revealed non-viable or no cancer cells after a rather short time from treatment. Conclusion: Monotherapy with carbon ion radiation may be an excellent treatment for localized prostate cancer with low risk.
引用
收藏
页码:290 / 294
页数:5
相关论文
共 25 条
[1]   Phase I/II clinical trials of carbon ion therapy for prostate cancer [J].
Akakura, K ;
Tsujii, H ;
Morita, S ;
Tsuji, H ;
Yagishita, T ;
Isaka, S ;
Ito, H ;
Akaza, H ;
Hata, M ;
Fujime, M ;
Harada, M ;
Shimazaki, J .
PROSTATE, 2004, 58 (03) :252-258
[2]   Diagnosis of prostate cancer in needle biopsies after radiation therapy [J].
Cheng, L ;
Cheville, JC ;
Bostwick, DG .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (10) :1173-1183
[3]  
Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035
[4]   Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients [J].
Crook, J ;
Malone, S ;
Perry, G ;
Bahadur, Y ;
Robertson, S ;
Abdolell, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (02) :355-367
[5]  
Crook JM, 1997, CANCER, V79, P81, DOI 10.1002/(SICI)1097-0142(19970101)79:1<81::AID-CNCR12>3.0.CO
[6]  
2-2
[7]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[8]   Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy [J].
D'Amico, AV ;
Moul, JW ;
Carroll, PR ;
Sun, L ;
Lubeck, D ;
Chen, MH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (18) :1376-1383
[9]   Scrutiny of the astro consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness [J].
Hanlon, AL ;
Hanks, GE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (03) :559-566
[10]  
*KAN PUB INC, 2001, GEN RUL CLIN PATH ST